(Q33398742)

26 July 2017

title

Drugs that inhibit complement (English)

1 reference

26 July 2017

Hubert Schrezenmeier

1

1 reference

26 July 2017

Britta Höchsmann

series ordinal

2

1 reference

26 July 2017

publication date

13 December 2011

1 reference

Transfusion and Apheresis Science

26 July 2017

published in

1 reference

26 July 2017

volume

46

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

87-92

1 reference

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Paroxysmal nocturnal hemoglobinuria: an acquired X-linked genetic disease with somatic-cell mosaicism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Detailed immunophenotypic characterization of different major and minor subsets of peripheral blood cells in patients with paroxysmal nocturnal hemoglobinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Natural history of paroxysmal nocturnal hemoglobinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Paroxysmal nocturnal hemoglobinuria and eculizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Identification of the haemoglobin scavenger receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

No scavenging and the hypertensive effect of hemoglobin-based blood substitutes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Evidence for a metabolic shift of arginine metabolism in sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Enhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Discrepant activity levels of von Willebrand factor-cleaving protease (ADAMTS-13) in congenital thrombotic thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Rapid regulation of platelet activation in vivo by nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Coagulation and endothelial dysfunction during longterm hyperdynamic porcine bacteremia--effects of selective inducible nitric oxide synthase inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Activated platelets in paroxysmal nocturnal haemoglobinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Atypical hemolytic-uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Eculizumab for Atypical Hemolytic–Uremic Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Infectious diseases. As E. coli outbreak recedes, new questions come to the fore

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

7 January 2021

Cold agglutinin disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

An open label clinical trial of complement inhibition in multifocal motor neuropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

New insights of an old defense system: structure, function, and clinical relevance of the complement system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

Therapeutic Complement Inhibition: New Developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2011.11.012

10.1016/J.TRANSCI.2011.11.012

7 January 2021

Identifiers

DOI

1 reference

26 July 2017

1 reference